Greater rates of patients with PsO achieved concurrent complete skin and nail clearance with bimekizumab vs adalimumab, ustekinumab, and secukinumab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback